Key Takeaways
- H1 revenue surged 53% YoY, broad-based: CDMO grew 72% and CRO 28%, with the CDMO ramp supported by late-stage and commercial programs scaling continuously.
- Margins expanded sharply, with more promised: EBITDA margin hit 27%, up 650 bps YoY, and management remains focused on a 28%-30% target range.
- The capex plan is a moving target: Management is evaluating multiple customer opportunities that could change both the type and scale of capex, stating the plan "might look very different in two months from now."
- New modalities are early and undefined: The company is building capabilities in ADCs, peptides, and oligonucleotides but management believes any defined strategy today is premature given how quickly the technology is shifting.
- What to watch next quarter: Whether the evolving capex plan firms up, any concrete announcements on ADC strategy, and if the historical H2 strength pattern holds for this year.
Financial Performance
- CDMO momentum: Revenue up 72% YoY in H1, driven by continuous scale-up of late-stage and commercial programs.
- CRO resilience: Revenue up 28% YoY, sustained by integrated program delivery and a significant increase in pharma clients over the last 4-5 years, which compensated for any biotech funding slowdown.
- Gross margin expansion: Gross margins expanded despite the share of discovery coming down, due to operational efficiency gained on certain commercial products, with no one-offs contributing.
- Other expenses ticked up: Rose from ~14% of revenue in Q2 FY25 to ~16% in Q2 FY26, with over half the increase driven by dollar appreciation and operational scale-up. Included one-off costs from working with top consulting firms for future-proofing and benchmarking.
- Consulting fees one-off: The double-digit crore consulting expense in Q2 was part of a planned three-to-four-month project to pivot toward global best practices; the magnitude will not repeat at the same level, though some consulting may continue sporadically.
Krishna Kanumuri: "Our whole strategy is to be a much bigger piece of the overall pie for our customers than just being a product service provider where a lot of other companies are focusing on at this point."
Capacity Expansion & Capex
- Scaling to 1,150 KL: Total installed capacity is being expanded from approximately 700 KL to 1,150 KL by end of FY27.
- FY26 capex on track: INR 700 crores planned for the full year, with INR 248 crores spent in H1.
- Capex plan is evolving: Management is evaluating several customer opportunities that could change both the type and scale of capex, and declined to provide FY27 guidance or total cost to reach 1,150 KL, stating the plan "might look very different in two months from now from where we are today."
- Capacity philosophy: The company builds for higher certainty of filling the pipeline rather than for blockbuster opportunities, prioritizing continuous supply and progression of pipelines over capacity for a few large products.
- Reactor commitment: As of now, all reactors for the expanded 1,150 KL capacity will be put up, as management has "reasonable confidence" the capacity will be needed, though this will be evaluated quarterly.
Krishna Kanumuri: "We don't build for that once-in-a-lifetime opportunity. We build more for a question of higher certainty of filling the pipeline rather than the blockbuster to come in."
New Modalities & Technology Platforms
- ADC progress: Commenced work with a large pharma on a long-term collaboration involving linker chemistry, and successfully completed bioconjugation work at discovery stage for another large pharma client.
- Peptides: Following a molecule by extending work with large pharma partners from discovery into development and scale-up capability.
- Oligonucleotides: Validating the phosphoramidite process for a commercial oligonucleotide molecule, with validation likely taking 15-18 months before becoming commercial.
- Flow chemistry: Successfully demonstrated commercial scale capability at the Bidar facility.
- XDC platform view: Management is looking at XDCs as a broader platform including peptides, PROTACs, and oligonucleotides, not just ADCs.
- Strategy is deliberately undefined: Management stated that anyone claiming to have a defined strategy for ADCs, peptides, or oligonucleotides today is premature, as the technology is shifting too quickly, requiring nimbleness and a customer-following approach.
- ADC announcement pending: The company is evaluating the ADC area very seriously and will make an announcement once more data is available.
Krishna Kanumuri: "All I will say is that right now, anybody today tells you that I have a strategy for ADCs, I have a defined strategy of peptide, I have defined strategy for oligonucleotides you can park it, because it's changing so quickly because the technology is shifting quickly."
Demand Environment & End-Market Dynamics
- China+1 tailwind intact: Companies are seeking to rebalance global supply chains, and new outsourcing business will be more geographically balanced; ongoing geopolitical volatility is not expected to impact the fundamental trend.
- Large pharma still early in India build-out: Large pharma innovators are still in the early stages of their India supply chain journey, expected to be a multi-year opportunity.
- Biotech funding to return: The perceived biotech funding slowdown has impacted the innovation pipeline, but the company offset the impact with pharma clients; management expects biotech funding will return sooner or later, adding upside.
- US innovator investment no threat: Management confirmed no material impact from US innovator companies investing domestically; customers indicated only final two stages (formulation) will be in the US, while advanced intermediates and RSMs will continue to be sourced from Sai.
- Product concentration stable: Product concentration has not significantly deviated from last year's disclosed range, per internal data, and dispatch data from exim sources does not show a reversal.
- No guaranteed volume protection: Management acknowledged that nothing can be put in writing to guarantee volume against sudden inventory corrections; customers work on forecasts that can be wrong, and the risk can only be minimized by increasing portfolio breadth. [13-14]
Krishna Kanumuri: "The best thing for you is to ask a pharma guy if he can give you a pipeline. He'll answer. There will be no way. We're basically dealing with a very, what do you call, unplanned business to a great extent."
Strategic Initiatives & New Entries
- Animal health entry: A dedicated Veterinary API facility was launched, marking a strategic entry into the animal health segment, with three of the top five global animal health companies already partnered.
- Vivarium expansion: Phase 2 expansion of the Vivarium at the Hyderabad R&D Center was completed, doubling the footprint and significantly enhancing preclinical assay capabilities.
- UK collaboration: A recent collaboration in the UK enhances the ability to serve clients across the development value chain from API development to drug products, manufacturing, and clinical trials.
- OEB-6 labs: In the process of building OEB-6 labs to strengthen capabilities in both Discovery and CMC.
- Compliance record: Over the past 12 months, 35 customer audits and 3 regulatory audits were completed with zero data integrity deviations and zero critical observations.
- AI impact on pipeline: Management does not believe AI fundamentally changes the volume of pipelines in the immediate future, and sees no material impact yet on later-stage molecules, though it may happen down the road.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 15%-20% revenue growth | Over 3-5 year period |
| EBITDA margin | 28%-30% EBITDA | No specific timeline; continued focus |
| Capacity expansion | Scale total installed capacity from ~700 KL to 1,150 KL | By end of FY27 |
| FY26 capex | INR 700 crores total | Full year FY26 |
| Oligonucleotide validation | Phosphoramidite process validation for commercial molecule | 15-18 months before becoming commercial |
| ADC announcement | Will announce once more data is available | No specific date |
| FY27 capex guidance | Will provide later; plan is evolving | No specific date |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Total revenue (H1 FY26) | ₹1,034 cr, +53% YoY over ₹675 cr in H1 FY25 |
| CDMO revenue (H1 FY26) | ₹667 cr, 64% of total revenue, +72% YoY |
| CRO revenue (H1 FY26) | ₹367 cr, 36% of total revenue, +28% YoY |
| EBITDA (H1 FY26) | ₹281 cr, +101% YoY over ₹140 cr in H1 FY25 |
| EBITDA margin (H1 FY26) | 27%, improved 650 bps YoY |
| PAT (H1 FY26) | ₹144 cr |
| Capex (H1 FY26) | ₹248 cr, against full-year plan of ₹700 cr |
| Revenue growth guidance | 15%–20% over a 3–5 year period |
| Total installed capacity | ~700 KL, scaling to 1,150 KL by end of FY27 |
| Late-stage pipeline additions | 3 products moved to late-stage during the quarter |
| Customer audits (trailing 12 months) | 35 customer audits, 3 regulatory audits, zero data integrity deviations, zero critical observations |
| Animal health partnerships | 3 of the top 5 global animal health companies partnered |
| Oligonucleotide validation timeline | 15–18 months before commercial for the molecule under validation |
| Consulting fees (one-off in other expenses) | Double-digit crores in Q2 FY26 |